Supply Chain Issues Cause Pfizer to Slash 2020 COVID-19 Vaccine Target, According to Reports
Friday, December 04, 2020
Challenges in Pfizer Inc’s supply chain for the raw materials used in its COVID-19 vaccine played a role in its decision to slash its 2020 production target, according to reports.
As GoLocal has reported, three pharmaceutical giants have announced success in the development of vaccines — Pfizer, Moderna, and Oxford/AstraZeneca, but there are complications with each.
This week, Pfizer was approved for use in the United Kingdom, making it the first country to do so.
GET THE LATEST BREAKING NEWS HERE -- SIGN UP FOR GOLOCAL FREE DAILY EBLAST"Pfizer has said in recent weeks that it anticipates producing 50 million doses of its COVID-19 vaccine this year. That is down from an earlier target of 100 million doses.
Pfizer’s vaccine relies on a two dose regimen, meaning 50 million doses is enough to inoculate 25 million people.
A company spokeswoman said the 'scale-up of the raw material supply chain took longer than expected.' She also cited later-than-expected results from Pfizer’s clinical trial as a reason for the smaller number of doses expected to be produced by the end of 2020.
The spokeswoman added that the modifications to Pfizer’s production lines are now complete and finished doses are being made at a rapid pace."
The Wall Street Journal was the first to report the news.
RI in Focus
In RI, Governor Gina Raimondo claimed Thursday she expects 29,000 vaccine doses through both Pfizer and Moderna by Christmas.
Related Articles
- NEW:: Kilmartin Says State Will Receive Over $647k from Pfizer Lawsuit
- Lethal Rejection: Pfizer Restricts Use of Its Drugs in Executions
- Warren Blasts Pfizer for Hiking Prices on Prescription Drugs
- 5 Major Coronavirus Developments - RI’s Conflicting Policies, Pfizer Vaccine, Are Outside Tents Safe
- United Kingdom First Country to Approve Use of Pfizer Vaccine - Vaccinations to Begin Next Week
